Medivir Ab

Medivir UK Ltd

Boehringer Ingelheim International Gmbh

Horst Wähling

Pia Kahnberg

Urszula Grabowska

Bertil Samuelsson

Magnus Nilsson

Bjorn Olof Classon

Peter Tomas Lind

Staffan Torssell

Genadiy Kalayanov

Susana Ayesa

Lourdes Odén

Ellen Hewitt

Daniel Jönsson

Karolina Ersmark

Mikael Pelcman

Vladimir Ivanov

Anna Karin Belfrage

Johan Bylund

Fernando Sehgelmeble

Hans Westerlind

Gennadiy Kalayanov

Cyrille Kuhn

Marie Leijonmarck

Megan Bertrand

Christian Brochu

Elise Ghiro

Claudio Sturino

Cysteine protease inhibitors

Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR, NHS(&#x2550;O)R, NHR, NRaRb, C(&#x2550;O)NHRor C(&#x2550;O)NRaRb wherein; Ris hydrogen, C-Calkyl, C-Calkylenecarbocyclyl, C-Calkyleneheterocyclyl; Ris C-Calkyl, C-Calkylenecarbocyclyl, C-Calkyleneheterocyclyl or NRaRb; Ris C-Calkyl, C-Calkylenecarbocyclyl, C-Calkyleneheterocyclyl, &#x2014;OC-Calkyl, &#x2014;OC-Calkylenecarbocyclyl, &#x2014;OC-Calkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R, Ror Rare optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C-Calkyl; Ry and Ry' are independently C-Calkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is &#x2014;CH&#x2014;, &#x2014;O&#x2014;, &#x2014;OC(&#x2550;O)NH&#x2014;, &#x2014;OC(&#x2550;O)&#x2014;, &#x2014;S&#x2014;, &#x2014;NH&#x2014;, &#x2014;NRa, &#x2014;NHS(&#x2550;O)&#x2014;, &#x2014;NHC(=0)NH&#x2014; or &#x2014;NHC(&#x2550;O)&#x2014;, &#x2014;NHC(&#x2550;S)NH&#x2014; or a bond; Ris an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections. 

Macrocyclic inhibitors of hepatitis C virus

Growing community of inventors

Huddinge, Sweden

Horst Wähling